CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 509-515

  Reding, M T ^a   Wu, H ^a   Krampf, M ^a   Okita, D K ^a   Diethelm Okita, B M ^a   Key, N S ^a   Conti Fine, B M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; CD4 ANTIGEN; EPITOPE; IMMUNOGLOBULIN G4; PEPTIDE LIBRARY;

ANTIBODY PRODUCTION; CONFERENCE PAPER; CONTROLLED STUDY; HELPER CELL; HEMOPHILIA; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032725319     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615873     Document Type: Conference Paper

References (90)

1. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol. 1994;47:208-217.
2. Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Hemost. 1995;21(4):382-389.
3. Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. Adv Exp Med Biol. 1995;386:35-45.
4. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Gungor T, Kornhuber B. Epidemiology of inhibitors in haemophilia A. Vox Sang. 1996;70(Suppl 1):2-8.
5. ® Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med. 1993;328:453-459.
6. De Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost. 1994;71:544-547.
7. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in hemophiliacs treated with low purity factor VIII. Lancet. 1993;342:462-464.
8. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594-598.
9. ®) in previously untreated patients (PUPs) with severe hemophilia A. Blood. 1992;80(suppl.1):229a.
10. Ljung R, Petrini P, Lindgren A, Tengborn L, Nilsson I. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:1550.
11. Lusher JM. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C. Ann Hematol. 1991;63:138-141.
12. Shulman NR, Hirschman RJ. Acquired hemophilia. Trans Assoc Am Physicians. 1969;82:388-397.
13. Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol 1996;9(2):331-354.
14. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature. 1984;312:337-342.
15. Lollar P. Structure and function of factor VIII. Adv Exp Med Biol. 1995;386:3-17.
16. Moussalli M, Pipe SW, Nichols WC, Ginsburg D, Hauri H-P, Kaufman RJ. Mistargeting of the lectin ERGIC-53 to the endoplasmic reticulum impairs the secretion of coagulation factors V and VIII. Blood. 1998;92(Suppl 1):474a.
17. Lusher JM, Spira J, Magill M. A four-year update of safety and efficacy of a second generation B-domain deleted factor VIII (R-VIII SQ) in previously untreated hemophilia A patients. Blood. 1998;92(Suppl 1):555a.
18. Naylor J, Banke A, Hassock S, Green, Glennelli G. Characteristic mRNA abnormality found in half the patients with severe hemophilia A is due to large gene inverstions. Hum Mol Genet. 1993;2:1773-1779.
19. Rossiter JP, Young M, Kimberland ML, Hutter P, Ketterling RP, Gitschier J, Horst J, Morris MA, Schaid DJ, de Moerloose P, et al. Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Hum Mol Genet. 1994;3(7):1035-1039.
20. Antonarakis S, Kazazian H Jr, Tuddenham E. Molecular etiology of factor VIII deficiency in hemophilia A. Hum Mutat. 1995;6:1-22.
21. McGinniss MJ, Kazazian HH Jr, Hoyer LW, Bi L, Inaba H, Antonarrakis SE. Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A. Genomics. 1993;15:392-398.
22. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood. 1988;71:344.
23. Tuddenham EGD, McVey JH. The genetic basis of inhibitor development in hemophilia A. Haemophilia. 1998;4:543-545.
24. Jacquemin MG, Saint-Remy JMR. Factor VIII immunogenicity. Haemophilia. 1998;4:552-557.
25. Gilles JGG, Jacquemin MG, Saint-Remy JMR. Factor VIII inhibitors. Thromb Haemost. 1997;78(1):641-646.
26. Hoyer LW, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol. 1994;31(2)(suppl.4):1-5.
27. Castaldi PA, Penny R. A macroglobulin with inhibitory activity against coagulation factor VIII. Blood. 1970;35:370-376.
28. McKelvey EM, Kwaan HC. An IgM circulating anticoagulant with factor VIII inhibitory activity. Ann Intern Med. 1972;77:571-575.
29. Glueck HI, Hong R. A circulating anticoagulant in IgA multiple myeloma: its modification by penicillin. J Clin Invest. 1965;44:1866-1881.
30. Gralnick HR, Flaum MA, Kessler CM, Zimbler H, Coller BS. IgA inhibitor to factor VIII/von Willebrand factor. Br J Haematol. 1985;59:149-158.
31. Nilsson IM, Berntorp E, Zettervall O, Dahlback B. Noncoagulation inhibitory factor Yin antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood. 1990;75(2):378-383.
32. Gilles JGG, Amout J, Vermylen J, Saint-Remy J-MR. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood. 1993;82(8):2452-2461.
33. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood. 1995;86(5):1811-1819.
34. Shima M, Nakai H, Scandella D, Tanaka I, Sawamoto Y, Kamisue S, Morichika S, Murakami T, Yoshioka A. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol. 1995;91:714-721.
35. Healey JF, Lubin IM, Nakai H, Saenko E, Hoyer LW, Scandella D, Lollar P. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem. 1995;270(24):14,505-14,509.
36. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood. 1998;92(1):136-142.
37. ® Study Groups. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood. 1997;89(10):3663-3671.
38. Batlle J, Gomez E, Rendal E, Torea J, Loures E, Couselo M, Vila P, Sedano C, Tusell X, Magallon M, Quintana M, Gonzalez-Boullosa R, Lopez-Fernandez MF. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol. 1996;72:321-326.
39. Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA. 1992;89:3795-3799.
40. Gilles JG, Saint-Remy J-MR. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest. 1994;94:1496-1505.
41. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton.' Immunol Today. 1991;12(5):154-158.
42. Morel-Kopp MC, Tchernia G, Lambert T, Verdy E, Schlegel N, Dreyfus M, Chateauvieux L, Kaplan C. Autoantibodies directed against the platelet GP complex Ib-IX in normal individuals. Blood. 1992;80(Suppl 1):49a.
43. + cells of myasthenia patients and healthy subjects. J Clin Invest. 1994;93:1020-1028.
44. + cells in Graves' disease patients and in healthy controls. J Autoimmun. 1995;8:685-698.
45. Burns J, Rosenzweig A, Zweiman B, Lisak RP. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol. 1983;81:435-440.
46. Pette M, Fujita K, Wilkinson D, Altmann DM, Trowsdale J, Giegerich G, Hinkkanen A, Epplen JT, Kappos L, Wekerle H. Myelin autoreactivity in multiple sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci USA. 1990;87:7968-7972.
47. Ota K, Matusi M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990;346:183-187.
48. Kuwana M, Medsger TA Jr, Wright TM. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J Clin Invest. 1995;96:586-596.
49. Ito Y, Nieda M, Uchigata Y, Nishimura M, Tokunaga K, Kuwata S, Obata F, Tadokoro K, Hirata Y, Omori Y, Juji T. Recognition of human insulin in the context of HLA-DRB1*0406 products by T cells of insulin autoimmune syndrome patients and healthy donors. J Immunol. 1993;151:5770-5776.
50. Hoffman RW, Takeda Y, Sharp GC, Lee DR, Hill DL, Kaneoka H, Caldwell CW. Human T cell clones reactive against U-small nuclear ribonucleoprotein autoantigens from connective tissue disease patients and healthy individuals. J Immunol. 1993;151:6460-6469.
51. Singer ST, Addiego JE Jr, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost. 1996;76(1):17-22.
52. Germain RH, Margulies DM. The biochemistry and cell biology of antigen processing and presentation. Ann Rev Immunol. 1993;11:403-450.
53. Abbas AK, Lichtman AH, Pober JS. T lymphocyte antigen recognition and activation. In: Abbas AK, Lichtman AH, Pober JS, eds. Cellular and Molecular Immunology. W.B. Saunders, Philadelphia; 1997:138-170.
54. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Ann Rev Immunol. 1996;14:233-258.
55. Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, Etster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the multi-center hemophilia cohort study. Am J Hematol. 1993;42:375-379.
56. Madhok R, Smith J, Jenkins A, Lowe GDO. T cell sensitization to factor VIII in hemophilia A? Br J Haematol. 1991;79:235-238.
57. Qian AJ, Collins M, Hoyer LW. Prevention of factor VIII inhibitors in murine hemophilia. Blood. 1998;92(Suppl 1):709a.
58. Abbas A, Murphy K, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787-793.
59. Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997;18:263-266.
60. + T-cell subsets and cytokines involved in peripheral tolerance. Immunol Today. 1997;18:533-538.
61. Qian A, Scott D, Hoyer L. T cell response to human factor VIII in murine hemophilia. Blood. 1997;90:599a.
62. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo V, Weiner H. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 1995;376:177-180.
63. Sloane-Lancaster J, Evavold B, Allen P. Th2 cells clonal anergy as a consequence of partial activation. J Exp Med. 1994;180:1195-1205.
64. Kappler J, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell. 1987;49:273-280.
65. Schwartz R. Acquisition of Immunological self-tolerance. Cell. 1989;57:1073-1081.
66. Matzinger P. Tolerance, danger, and the extended family. Ann Rev Immunol. 1994;12:991-1045.
67. Nossal G. Choices following antigen entry: antibody formation or immunologic tolerance? Ann Rev Immunol. 1995;13:1-27.
68. Weiner H, Friedman A, Miller A, Khoury SJ, Al-Sabbagh, A, Santos L, Sayegh M, Nussenblatt RB, Trenthan DE, Hafler AD. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol. 1994;12:809-837.
69. Chen Y, Inobe J, Kuchroo V, Baron J, Janeway CJ, Weiner H. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA. 1996;93:388-391.
70. Friedman A, Weiner HL. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA. 1994;91:6688-6692.
71. Gregerson D, Obritsch W, Donoso L. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs. high dose feeding protocols. J Immunol. 1993;151:5751-5761.
72. Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Rainse CS, Goverman J, Lenardo M. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 1994;263:1139-1143.
73. Vardhachary AS, Perdow SN, Hu C, Ramanarayanan M, Salgame P. Differential ability of T cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci USA. 1997;94:5778-5783.
74. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, Sato T, Reed JD, Green D, Swain SL. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med. 1997;185:1837-1849.
75. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989;19:2237-2242.
76. Ho PC, Mutch DA, Winkel KD, Saul AJ, Jones GL, Doran, TJ, Rzepczyk CM. Identification of two promiscuous T cell epitopes from tetanus toxin. Eur J Immunol. 1990;20:477-483.
77. Reece JC, Geysen HM, Rodda SJ. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J Immunol. 1993;151:6175-6184.
78. Protti MP, Manfredi AA, Horton BM, Bellone M, Conti-Tronconi BM. Myasthenia Gravis: recognition of a human autoantigen at the molecular level. Immunol Today. 1993;14:363-368.
79. + T cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects. Eur J Immunol. 1995;25:3207-3214.
80. + T cells on tetanus toxoid: identification of immunodominant sequence segments. J Infect Dis. 1997;175:382-391.
81. + T cells epitopes. J Clin Invest. 1997;100:3027-3035.
82. Karachunski PI, Ostlie NS, Okita DK, Garman R, Conti-Fine BM. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis. J Neuroimmunol. 1999;93:108-121.
83. Rudensky AY, Preston-Hurburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptide bound to MHC class II molecules. Nature. 1991;353:622-627.
84. d. Science. 1992;256:1817-1820.
85. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994;368:215-221.
86. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993;178:27-47.
87. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LR, Lin RY, Strober W, Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935-946.
88. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IR, Debatin KM, Fisher A, de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-1349.
89. Johnson JG, Jenkins MK. The role of anergy in peripheral T cell unresponsiveness. Life Sci. 1994;55:1767-1780.
90. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med. 1996;184:1-8.